Ortega Miguel A, Fraile-Martínez Oscar, Asúnsolo Ángel, Buján Julia, García-Honduvilla Natalio, Coca Santiago
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences and Networking Biomedical Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), University of Alcalá, Alcalá de Henares, Madrid, Spain.
Ramón y Cajal Institute of Healthcare Research (IRYCIS), Madrid, Spain.
J Oncol. 2020 Mar 9;2020:9258396. doi: 10.1155/2020/9258396. eCollection 2020.
Breast cancer is the cancer with the highest prevalence in women and is the number-one cause of cancer mortality worldwide. Cell transduction is a fundamental process in the development and progression of cancer. Modifications in various cell signalling pathways promote tumour cell proliferation, progression, and survival. The PI3K/Akt/mTOR pathway is an example of that, and it is involved in growth, proliferation, survival, motility, metabolism, and immune response regulation. Activation of this pathway is one of the main causes of cancer cell resistance to antitumour therapies. This makes PI3K/Akt/mTOR signalling a crucial object of study for understanding the development and progression of this disease. Thus, this pathway may have a role as a potential therapeutic target, as well as prognostic and diagnostic value, in patients with breast cancer. Despite the existence of selective PI3K/Akt/mTOR pathway inhibitors and current clinical trials, the cellular mechanisms are not yet known. The present review aims to understand the current state of this important disease and the paths that must be forged.
乳腺癌是女性中患病率最高的癌症,也是全球癌症死亡的首要原因。细胞转导是癌症发生和发展的一个基本过程。各种细胞信号通路的改变促进肿瘤细胞的增殖、进展和存活。PI3K/Akt/mTOR通路就是一个例子,它参与生长、增殖、存活、迁移、代谢和免疫反应调节。该通路的激活是癌细胞对抗肿瘤治疗产生耐药性的主要原因之一。这使得PI3K/Akt/mTOR信号成为理解这种疾病发生和发展的关键研究对象。因此,这条通路在乳腺癌患者中可能具有作为潜在治疗靶点的作用,以及预后和诊断价值。尽管存在选择性PI3K/Akt/mTOR通路抑制剂以及当前的临床试验,但细胞机制尚不清楚。本综述旨在了解这种重要疾病的现状以及必须探索的途径。